Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Oxurion (vh ThromboGenics)   /   Oxurion in 2019

Aandeel OXURION BRU:OXUR.BL, BE0974487192

Laatste koers (eur) Verschil Volume
0,300   +0,009   (+2,92%) Dagrange 0,280 - 0,300 30.227   Gem. (3M) 9,2M

Oxurion in 2019

Volgen
180 Posts
Pagina: «« 1 2 3 4 5 6 ... 9 »» | Laatste | Omlaag ↓
  3. forum rang 4 jus1711 4 februari 2019 16:18
    Leuven, Belgium, 4 February 2019 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview and clinical update at the 2019 BIO CEO & Investor Conference. The presentation will take place at 11:15 a.m. EST on Tuesday, Feb. 12, 2019 in the Herald/Soho room at the New York Marriott Marquis.

    Oxurion’s management team will also hold one-on-one meetings with institutional investors and analysts Feb. 11-14 in New York.

    Patrik De Haes, MD, CEO of Oxurion NV, commented: “It is a particularly pivotal time at Oxurion given the progress of our 4 clinical programs, each slated to read out in the second half of 2019. We look forward to providing a company update at the BIO CEO & Investor Conference as we continue to advance our pipeline of disease-modifying therapies in the clinic and remain confident in the potential of each therapy to preserve vision in patients with diabetic eye disease.”
  20. relpinda 5 maart 2019 20:49
    UPDATE
    Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
    Nieuws via RSS voor Oxurion (ex ThromboGenics)
    28 februari 2019 08:01
    Leuven, Belgium, 28 February 2019 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces today that it will present at the 9th European Society of Retina Specialists (EURETINA) Winter Meeting, which is being held March 1-2, 2019 in Prague, Czech Republic at the Clarion Congress Hotel.

    The poster "Targeting plasma kallikrein with a novel bicyclic peptide inhibitor alleviates diabetic retinopathy disease hallmarks in a preclinical rat model" shows results of the inhibitory effect of repeated administration of THR-149, Oxurion's novel plasma kallikrein (PKal) inhibitor, on retinal vascular leakage and inflammation in the diabetic rat STZ model, compared to vehicle-treated eyes. These positive results highlight THR-149's potential as a treatment option for diabetic macular edema (DME). Oxurion is currently conducting a Phase 1 clinical study evaluating the safety of THR-149 in DME patients with initial data read out expected towards the end of 2019.

    Patrik De Haes, M.D., CEO of Oxurion nv, commented: "We look forward to presenting the results of our preclinical research with THR-149 in the field of DME at the EURETINA Winter Meeting. The results of the study demonstrate the potential therapeutic benefits of THR-149, our plasma kallikrein inhibitor, on the key disease hallmarks of DME including retinal vascular leakage and inflammation. These results further substantiate the disease-modifying capabilities of this novel drug candidate and its potential to address the clear unmet need for improved treatment options for diabetic eye disease."

    END

    For further information please contact:

    Oxurion NV
    Wouter Piepers,
    Global Head of Corp Coms & Investor relations
    +32 16 75 13 10 / +32 478 33 56 32
    wouter.piepers@oxurion.com

    LZA
180 Posts
Pagina: «« 1 2 3 4 5 6 ... 9 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee